Laboratorios Rovi : Q4 conference call highlights
>Conference call highlights - I/Risvan. They expect to obtain the FDA’s marketing authorisation at the end of March. II/ Okedi. The management stated that the group’s performance was above its initial expectations. In the last year they have launched the product in key markets in Europe like Germany or Spain, among others, and expect to keep the expansion in FY 2024 (Nordics). They believe the sales peak in Europe will come in 3-4 years. III/Letrozole. The company ...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.